ZA201307169B - Neuroprotective peptides - Google Patents
Neuroprotective peptidesInfo
- Publication number
- ZA201307169B ZA201307169B ZA2013/07169A ZA201307169A ZA201307169B ZA 201307169 B ZA201307169 B ZA 201307169B ZA 2013/07169 A ZA2013/07169 A ZA 2013/07169A ZA 201307169 A ZA201307169 A ZA 201307169A ZA 201307169 B ZA201307169 B ZA 201307169B
- Authority
- ZA
- South Africa
- Prior art keywords
- neuroprotective peptides
- neuroprotective
- peptides
- Prior art date
Links
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466966P | 2011-03-24 | 2011-03-24 | |
| PCT/IL2012/050104 WO2012127475A1 (en) | 2011-03-24 | 2012-03-22 | Neuroprotective peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201307169B true ZA201307169B (en) | 2014-05-28 |
Family
ID=45999925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2013/07169A ZA201307169B (en) | 2011-03-24 | 2013-09-18 | Neuroprotective peptides |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140045764A1 (enExample) |
| EP (1) | EP2688582B1 (enExample) |
| JP (1) | JP5960793B2 (enExample) |
| KR (1) | KR20140036164A (enExample) |
| CN (1) | CN103648517B (enExample) |
| AU (1) | AU2012232642B2 (enExample) |
| BR (1) | BR112013024323A2 (enExample) |
| CA (1) | CA2830792A1 (enExample) |
| EA (1) | EA201391387A1 (enExample) |
| MX (1) | MX2013010910A (enExample) |
| SG (1) | SG193418A1 (enExample) |
| WO (1) | WO2012127475A1 (enExample) |
| ZA (1) | ZA201307169B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201220899D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived pegylated peptides |
| KR101901669B1 (ko) * | 2016-01-27 | 2018-09-28 | 경상대학교산학협력단 | 아디포넥틴 수용체 활성화 신규 펩티드를 유효성분으로 포함하는 신경질환의 예방, 개선 또는 치료용 조성물 |
| US10981956B2 (en) | 2016-03-31 | 2021-04-20 | Senju Pharmaceutical Co., Ltd. | Neuroprotective peptide |
| WO2017170926A1 (ja) * | 2016-03-31 | 2017-10-05 | 千寿製薬株式会社 | 神経保護ペプチド |
| CN111344300B (zh) | 2017-11-14 | 2024-08-30 | 千寿制药株式会社 | Pacap的稳定化肽 |
| AU2019374743B2 (en) | 2018-11-08 | 2022-03-03 | Neovasc Tiara Inc. | Ventricular deployment of a transcatheter mitral valve prosthesis |
| ES2991433T3 (es) | 2019-05-14 | 2024-12-03 | Senju Pharma Co | Péptido de PACAP estabilizado |
| WO2020230869A1 (ja) | 2019-05-14 | 2020-11-19 | 千寿製薬株式会社 | Ｐａｃａｐペプチド又はｐａｃａｐの安定化ペプチドを含む神経栄養性角膜炎の予防又は治療用組成物 |
| CN112569351B (zh) * | 2020-12-16 | 2021-10-15 | 南通大学 | Cd44抗体在制备治疗帕金森疾病的药物中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| JPH08511419A (ja) * | 1993-06-18 | 1996-12-03 | ヤルカネン、シルパ | 組成物およびＣＤ４４ｖ６に対するモノクローナル抗体を用いる診断方法 |
| WO1995019183A1 (en) * | 1994-01-18 | 1995-07-20 | President And Fellows Of Harvard College | Cd44 expression in smooth muscle cells |
| DE19653607A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Int | Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen |
| AU3448899A (en) * | 1998-01-24 | 1999-08-09 | Bristol-Myers Squibb Company | Artificial proteoglycans |
| EP1647556B1 (en) * | 2004-10-14 | 2010-05-19 | Karlsruher Institut für Technologie | Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors |
| EP2167692B1 (en) * | 2007-07-10 | 2013-05-22 | Neurim Pharmaceuticals (1991) Ltd. | Cd44 splice variants in neurodegenerative diseases |
| EP2266593A1 (en) * | 2009-06-24 | 2010-12-29 | Karlsruher Institut für Technologie | Use of CD44v6 in the treatment of ophthalmic diseases |
-
2012
- 2012-03-22 CA CA2830792A patent/CA2830792A1/en not_active Abandoned
- 2012-03-22 SG SG2013068499A patent/SG193418A1/en unknown
- 2012-03-22 CN CN201280014793.1A patent/CN103648517B/zh active Active
- 2012-03-22 US US14/007,010 patent/US20140045764A1/en not_active Abandoned
- 2012-03-22 EP EP12716661.9A patent/EP2688582B1/en active Active
- 2012-03-22 WO PCT/IL2012/050104 patent/WO2012127475A1/en not_active Ceased
- 2012-03-22 KR KR1020137027914A patent/KR20140036164A/ko not_active Withdrawn
- 2012-03-22 MX MX2013010910A patent/MX2013010910A/es not_active Application Discontinuation
- 2012-03-22 AU AU2012232642A patent/AU2012232642B2/en active Active
- 2012-03-22 JP JP2014500540A patent/JP5960793B2/ja active Active
- 2012-03-22 EA EA201391387A patent/EA201391387A1/ru unknown
- 2012-03-22 BR BR112013024323A patent/BR112013024323A2/pt not_active Application Discontinuation
-
2013
- 2013-09-18 ZA ZA2013/07169A patent/ZA201307169B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013024323A2 (pt) | 2017-06-13 |
| WO2012127475A1 (en) | 2012-09-27 |
| SG193418A1 (en) | 2013-10-30 |
| MX2013010910A (es) | 2014-03-27 |
| EP2688582B1 (en) | 2017-02-15 |
| CN103648517A (zh) | 2014-03-19 |
| AU2012232642B2 (en) | 2016-12-08 |
| US20140045764A1 (en) | 2014-02-13 |
| JP2014510101A (ja) | 2014-04-24 |
| EA201391387A1 (ru) | 2014-01-30 |
| KR20140036164A (ko) | 2014-03-25 |
| CA2830792A1 (en) | 2012-09-27 |
| EP2688582A1 (en) | 2014-01-29 |
| CN103648517B (zh) | 2016-04-20 |
| AU2012232642A1 (en) | 2013-10-17 |
| JP5960793B2 (ja) | 2016-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201601840RA (en) | P53 activating peptides | |
| IL231604B (en) | Therapeutic peptides | |
| ZA201309174B (en) | Polypeptides | |
| IL233280A0 (en) | Cell-penetrating peptides | |
| EP2857033A4 (en) | PEPTIDE WITH SKIN PERMEATION | |
| GB201012651D0 (en) | Peptides | |
| ZA201307169B (en) | Neuroprotective peptides | |
| GB201111183D0 (en) | Peptide | |
| EP2753641A4 (en) | NEUROPROTECTIVE CELL PENETRATING PEPTIDES | |
| GB201115910D0 (en) | Peptides | |
| ZA201503127B (en) | Peptides | |
| GB201200555D0 (en) | Peptide | |
| GB201204868D0 (en) | Peptides | |
| GB201223114D0 (en) | Novel peptide | |
| PT2891663T (pt) | Péptidos derivados de psf1 | |
| IL228354A0 (en) | Neuroprotective peptides | |
| GB201115014D0 (en) | Peptides | |
| GB201220328D0 (en) | Peptides | |
| GB201211740D0 (en) | Peptides | |
| GB201207895D0 (en) | Peptides | |
| GB201200509D0 (en) | Peptides | |
| GB201105653D0 (en) | Anti-microbial peptides | |
| GB201221414D0 (en) | Trans-locating peptide | |
| GB201200624D0 (en) | Peptide | |
| GB201200623D0 (en) | Peptide |